Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat.
Electrophysiological recordings were made in anaesthetized rats to investigate the mode of function of high-frequency stimulation of the subthalamic nucleus used as a therapeutic approach for Parkinson's disease. High-frequency electrical stimulation of the subthalamic nucleus (130 Hz) induced a net decrease in activity of all cells recorded around the site of stimulation in the subthalamic nucleus. It also caused an inhibition of the majority of neurons recorded in the substantia nigra pars reticulata in normal rats (94%) and in rats with 6-hydroxydopamine lesions of the substantia nigra pars compacta (90%) or with ibotenic acid lesions of the globus pallidus (79.5%). The majority of cells recorded in the ventrolateral nucleus of the thalamus responded with an increase in their activity (84%). These results show that high-frequency stimulation of the subthalamic nucleus induces a reduction of the excitatory glutamatergic output from the subthalamic nucleus which results in deactivation of substantia nigra pars reticulata neurons. The reduction in tonic inhibitory drive of nigral neurons induces a disinhibition of activity in the ventrolateral motor thalamic nucleus, which should result in activation of the motor cortical system.
Laboratoire de Neurobiologie préclinique, INSERM U. 318, CHU-Pavillon B, BP 217, 38043, Grenoble, France. Abdelhamid.Benazzouz@ujf-grenoble.fr
A
A
Benazzouz
D M
DM
Gao
Z G
ZG
Ni
B
B
Piallat
R
R
Bouali-Benazzouz
A L
AL
Benabid
D018663:Adrenergic Agents; D000818:Animals; D004558:Electric Stimulation; D005917:Globus Pallidus / Q000293:injuries / Q000502:physiology*; D008297:Male; D016627:Oxidopamine; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000293:injuries / Q000502:physiology*; D020531:Subthalamic Nucleus / Q000502:physiology*; D020651:Ventral Thalamic Nuclei / Q000502:physiology*
D018663:Adrenergic Agents; D016627:Oxidopamine